Systemic therapy in hepatocellular carcinoma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Liver Disease

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cld.2011.03.002PMID 21689622PMCID PMC3758582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma.

  2016cited by this paper
• An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC).

  2016cited by this paper
• Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

  2010cited by this paper
• Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?

  2010cited by this paper
• The role of signaling pathways in the development and treatment of hepatocellular carcinoma

  2010cited by this paper
• Targeted therapies: Sunitinib versus interferon-α in metastatic RCC

  2010cited by this paper
• Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.

  2010cited by this paper
• Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

  2010cited by this paper
• A phase I study of pazopanib in patients with advanced hepatocellular carcinoma.

  2009cited by this paper
• Bevacizumab: current indications and future development for management of solid tumors.

  2009cited by this paper
• Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

  2009cited by this paper
• Major achievements in hepatocellular carcinoma.

  2009cited by this paper
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Adoptive cell therapy for the treatment of patients with metastatic melanoma.

  2009cited by this paper
• Bevacizumab: current indications and future development for management of solid tumors

  2009cited by this paper
• A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis.

  2009cited by this paper
• Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

  2009cited by this paper
• New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication

  2009cited by this paper
• New trends in epidermal growth factor receptor-directed monoclonal antibodies.

  2009cited by this paper
• Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

  2009cited by this paper
• Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma

  2009cited by this paper
• Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma

  2008cited by this paper
• Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• 28 PILOT STUDY OF SIROLIMUS IN CIRRHOTIC PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

  2008cited by this paper
• Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

  2008cited by this paper
• The impact of mTOR inhibitors on the development of malignancy.

  2008cited by this paper
• Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

  2008cited by this paper
• A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

  2007cited by this paper
• Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007cited by this paper
• Long‐acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double‐blind study

  2007cited by this paper
• Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

  2007cited by this paper
• Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

  2007cited by this paper
• Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC)

  2007cited by this paper
• Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis

  2006cited by this paper
• Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

  2006cited by this paper
• A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

  2005cited by this paper
• Resection and Liver Transplantation for Hepatocellular Carcinoma

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC)

  2005cited by this paper
• Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic Cells: A Clinical Trial

  2005cited by this paper
• Use of tamoxifen in advanced‐stage hepatocellular carcinoma

  2005cited by this paper
• Antiangiogenic therapy for cancer: current and emerging concepts.

  2005cited by this paper
• A phase II trial of continuous infusion of 5‐fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma

  2005cited by this paper
• Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

  2004cited by this paper
• Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

  2004cited by this paper
• Primary liver cancer: worldwide incidence and trends.

  2004cited by this paper
• Chemoembolization for hepatocellular carcinoma.

  2004cited by this paper
• Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

  2003cited by this paper
• A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

  2002cited by this paper
• High‐dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

  2002cited by this paper
• Prospective Pilot Study of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor and Interferon-&ggr; in Patients With Inoperable Hepatocellular Carcinoma

  2002cited by this paper
• Multidrug resistance gene (MDR‐1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection

  2001cited by this paper
• A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.

  2001cited by this paper
• A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

  2001cited by this paper
• Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

  2000cited by this paper
• Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study

  2000cited by this paper
• Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

  2000cited by this paper
• Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.

  1999cited by this paper
• Expression of vascular endothelial growth factor in human hepatocellular carcinoma

  1998cited by this paper
• Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

  1998cited by this paper
• Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.

  1997cited by this paper
• Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.

  1997cited by this paper
• Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.

  1995cited by this paper
• Combined Transarterial Targeting Locoregional Immunotherapy-Chemotherapy for Patients with Unresectable Hepatocellular Carcinoma: A New Alternative for an Old Problem

  1995cited by this paper
• Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial

  1995cited by this paper
• A prospective randomized trial

  1995cited by this paper
• Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

  1993cited by this paper
• A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma

  1993cited by this paper
• Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial

  1993cited by this paper
• Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

  1988cited by this paper
• A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

  1987cited by this paper
• Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.

  1984cited by this paper
• Induction of remission in hepatocellular carcinoma: A comparison of VP 16 with adriamycin

  1983cited by this paper
• Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication

  1975cited by this paper

• Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis

  2025cites this paper
• Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers.

  2022cites this paper
• Ethanolic extract of Coleus aromaticus leaves impedes the proliferation and instigates apoptotic cell death in liver cancer HepG2 cells through repressing JAK/STAT cascade.

  2022cites this paper
• Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations

  2022cites this paper
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

  2021cites this paper
• JAK/STAT signaling in hepatocellular carcinoma

  2020cites this paper
• A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.

  2020cites this paper
• Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib

  2019cites this paper
• CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma

  2018cites this paper
• Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma

  2018cites this paper
• Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma

  2016cites this paper
• Accomplices in crime: The diabolical liaison between protein tyrosine phosphatase 1B and ras in hepatocellular carcinoma

  2016cites this paper
• Liver diseases: what is known so far about the therapy with human amniotic membrane?

  2016cites this paper
• A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel

  2016cites this paper
• CD147/Basigin: a Warburg oncogene in hepatocellular carcinoma?

  2016cites this paper
• Therapeutic Strategies for Hepatocellular Carcinoma: New Advances and Challenges

  2015cites this paper
• Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

  2015cites this paper
• Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish

  2015cites this paper
• When good transforming growth factor‐β turns bad in hepatocellular carcinoma: Axl takes the stage

  2015cites this paper
• Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer

  2015cites this paper
• Molecularly targeted therapies for human hepatocellular carcinoma: should we start from β-catenin inhibition?

  2015cites this paper
• Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.

  2015cites this paper
• A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma

  2015cites this paper
• Title Copy number gain of granulin-epithelin precursor ( GEP ) at chromosome 17 q 21 associates with overexpression in human liver cancer

  2015cites this paper
• Estradiol, farnesoid X receptor, and altered metabolism in pregnancy

  2014cites this paper
• New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment

  2014cites this paper
• Inhibitory Effects of Nobiletin on Hepatocellular Carcinoma In Vitro and In Vivo

  2014cites this paper
• Hepatic Tumors in Childhood

  2014cites this paper
• An oncolytic adenovirus regulated by a radiation‐inducible promoter selectively mediates hSulf‐1 gene expression and mutually reinforces antitumor activity of I131‐metuximab in hepatocellular carcinoma

  2013cites this paper
• Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.

  2012cites this paper